| Name | Title | Contact Details |
|---|
NOBLE MEDICAL, Inc. is a Brookfield, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specific`s Reveal™ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specific`s unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specific`s system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections. Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing.
Cytori Therapeutics is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CeQur is dedicated to helping people with type 2 diabetes manage their disease by developing and commercializing simple drug delivery devices that can be easily integrated into daily life. The company`s lead product, PaQ, is a wearable insulin delivery device that delivers both basal and bolus insulin for 3 days at a time. Its simple, discreet design enables people to easily experience the benefits of intensive insulin therapy, while remaining free from the burdens of daily insulin injections. CeQur SA was established in January 2008 as a spinout from Danfoss A/S, a global Danish industrial products group that developed the initial concept of the CeQur technology. CeQur recently completed a clinical study evaluating PaQ among people with type 2 diabetes with positive results. The company has advanced the technology to a commercial product obtaining a CE mark for PaQ in 2012. CeQur is headquartered in Horw, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts.